alt

button external

This is the RTE module within the accordion module.

The quick brown fox jumps over the lazy dog

The quick brown fox jumps over the lazy dog

The quick brown fox jumps over the lazy dog

The quick brown fox jumps over the lazy dog

The quick brown fox jumps over the lazy dog

The quick brown fox jumps over the lazy dog

The quick brown fox jumps over the lazy dog

Click here

This is a link without a button

• List item 1
• List item 2
• List item 3

Para large font test

Page header

Section header

Paragraph header

Bold paragraph text 

Italic paragraph text

Aligned left text

Center-aligned text

Align right text

• Item 1
• Item 2
• Item 3

1. Exhibit A
2. Exhibit B
3. Exhibit C 

^{Test Test Superscript option}

Test

test 2

Dominique started his career as a General Practitioner in France. He joined GSK in 1996¹ from Ciba Geigy, where he held various marketing and management positions. In 2000, Dominique was appointed General Manager of GSK France. He then became SVP, Southern & Eastern Europe Area Director and then Head of GSK Personalised Medicine Strategy.

Deborah joined GSK in 1996² and is³ currently⁴ SVP Primary Care in US Pharmaceuticals,⁵ prior to which she led the US⁶ Vaccines business. She⁷ brings a wealth of experience to ViiV⁸ Healthcare⁹ having lived and worked in Europe¹⁰, Asia¹¹ and the USA¹² and a strong¹³ track record of performance in both¹⁴ specialty and primary care. She led the HIV¹⁵ business in the UK¹⁶ before heading the HIV Centre of Excellence for Pharma¹⁷ Europe, and held international roles as General Manager of Australia¹⁸ and New Zealand¹⁹ and SVP Central and Eastern Europe.

Andrew Witty, Chief Executive Officer, GSK, said: “I want to thank Dominique for the success achieved under his leadership. Since he became CEO of ViiV Healthcare at its creation seven years ago²⁰, the business has successfully launched new medicines, established an innovative pipeline and built a strong reputation with healthcare professionals and the HIV community. With these foundations in place, Dominique leaves ViiV Healthcare in a great position. Emma²¹ and I are delighted that Deborah²² will be his successor. She is a dynamic leader who has a real passion to deliver for patients and customers and we are confident that she will continue to develop the business successfully to make a difference for people living with HIV, their families and society as a whole.”

Dominique Limet said: “Establishing²³ and then leading ViiV Healthcare for the past seven years has been an incredible honour and extremely fulfilling personally. I have had the pleasure to work with an exceptional team and am proud of how the business has grown to its current position as a leader in HIV therapy. We have delivered scientific innovation, while listening and better understanding the needs of people living with HIV, allowing us to both do good and do well as a business. The future looks extremely promising for ViiV Healthcare.”

David Redfern²⁴, Chairman of ViiV Healthcare, said: “Dominique has been an outstanding leader of ViiV Healthcare. He has helped to create an entirely new company at the forefront of HIV research and treatment development, with a culture that both inspires and delivers strong business performance. I have very much enjoyed working with him and wish him the very best for the future²⁵.

I also look forward to working with Deborah, a leader who is known for listening to the customer and to her teams, and someone I know is very passionate about innovation in HIV therapy and access.”

Deborah Waterhouse said: “ViiV Healthcare²⁶ has an impeccable reputation for strong performance and a culture that thrives on challenge. I’m honoured to have the opportunity to lead such an exciting endeavour, and to build on the advances that Dominique and the ViiV Healthcare organisation have made to HIV treatment and care.”

Cheryl MacDiarmid^{2728  29}has been appointed to succeed Deborah as SVP US Pharmaceuticals Primary Care. Cheryl has served as VP US Primary Care Sales since early 2015 and been instrumental in shaping the US Primary Care strategy, delivering performance and renewing the culture of patient and customer focus. She brings 20 years of deep experience in establishing key brands and building businesses in the US and Canada, and is known for creating and leading engaged, high-performing teams.

GSK³⁰ – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.

ViiV Healthcare - a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV. Shionogi joined in October 2012. The company’s aim is to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and new HIV medicines, as well as support communities affected by HIV.

For more information on the company, its management, portfolio, pipeline, and commitment, please visit www.viivhealthcare.com.

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2015.

invalid anchor test³¹